Latest Breaking News On - Junshi - Page 1 : comparemela.com

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
bmj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bmj.com Daily Mail and Mail on Sunday newspapers.

United-states
Japan
Taiwan
Junshi
Anhui
China
Helsinki
Eteläuomen-läi
Finland
Germany
Qilu
Gansu

AI-Driven Optical Network Technology Transformation: China FIBERTalk 2024 Takes Place in China's Optics Valley

WUHAN, China, May 23, 2024 /PRNewswire/ Co-hosted by the Fiber Network Council APAC and Yangtze Optical Fibre and Cable Joint Stock Limited Company , China FIBERTalk 2024 was held in China s.

Junshi
Anhui
China
Philippines
Milan
Lombardia
Italy
Wuhan
Hubei
Yangtze
China-general
Chengliang

Coherus again axes staff, with 30% of roles on chopping block amid 'sharpened focus' on cancer drugs

Coherus again axes staff, with 30% of roles on chopping block amid 'sharpened focus' on cancer drugs
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Canada
California
United-states
China
Junshi
Anhui
Canadian
Chinese
Paul-reider
Coherus-biosciences
Amgen-neulasta

Garsorasib Plus Cetuximab Shows Early Efficacy in Heavily Pretreated KRAS G12C+ CRC

The combination of garsorasib and cetuximab elicited responses and was found to be well tolerated in heavily pretreated patients with KRAS G12C–mutated colorectal cancer.

Junshi
Anhui
China
Guangzhou
Guangdong
Rui-hua-xu
Keymed-bioscience
Astrazeneca
Bristol-myers-squibb
Clinical-research
Sun-yat-sen-university-cancer-center
Colorectal-cancer

Fierce Pharma Asia—Merck KGaA and Hengrui's PARP deal; Novartis and Takeda's employee dispute; toripalimab's FDA nod

Fierce Pharma Asia—Merck KGaA and Hengrui's PARP deal; Novartis and Takeda's employee dispute; toripalimab's FDA nod
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

China
Junshi
Anhui
Japan
Japanese
Coherus-biosciences
Daiichi-sankyo
Astrazeneca-lynparza
Denny-lanfear
Merck-kga
Merck-co
Merck-kgaa